PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
International Stem Cell Corporation

Press Release


Receive press releases from International Stem Cell Corporation: By Email RSS Feeds:

International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment from Human Parthenogenetic Stem Cells


International Stem Cell Corporation, an international pioneer and leader in stem cell research, begins its second pre-clinical phase of testing retinal pigment epithelium (RPE) derived from human parthenogenetic stem cells for the treatment of retinal diseases.

Oceanside, CA, March 24, 2010 --(PR.com)-- International Stem Cell Corporation (OTCBB: ISCO) announced that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic stem cells. Follow on pre-clinical experiments will be conducted to rescue vision in disease models.

Retinal pigment epithelium (RPE) has been derived from parthenogenetic stem cells by ISCO scientists in close collaboration with UCI scientists. The RPE cells will be tested for the presence of specific markers and for functional activity.

Retinal pigment epithelium plays a critical role in maintaining proper eye function. Loss of function or dysfunction of RPE is involved in a range of disabling eye conditions, particularly age-related macular degeneration (AMD) that is the major cause of vision loss in seniors.

Encouraging data from animal models have shown that visual degradation caused by AMD can be slowed through the transplantation of RPE. One of the major barriers for this therapy is the lack of sufficient RPE cells from suitable donated tissue.

According to Dr. Hans Keirstead, Professor of Anatomy and Neurobiology at the University of California, Irvine, "The derivation of RPE from stem cells will allow the availability of an unlimited source of RPE for transplantation." Referring to the upcoming work with ISCO, Dr. Keirstead said, "This research will enable us to then test the ability of these cells to restore vision in rodent models of retinal degeneration."

Dr. Nikolay Turovets, ISCO's Director of Research and Therapeutic Development, says, "RPE derived from human parthenogenetic stem cells can overcome the problem of immune-matching for transplantation since ISCO's parthenogenetic stem cell lines can be made to carry the most common sets of immune genes found among various racial groups. That is why the differentiated derivatives from one hpSC line may be transplanted into millions of people."

About International Stem Cell Corporation (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of immune-matched therapeutic cells to minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. This offers the potential to create the first true stem cell bank, UniStemCell™, while avoiding the ethical issue of using fertilized eggs. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology. More information is available at ISCO's website.

Forward-Looking Statements
Statements pertaining to anticipated technological developments and therapeutic applications, and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

###
Contact Information
International Stem Cell Corporation
Jim Goyjer
310-207-3361
Contact
www.internationalstemcell.com
Kenneth C. Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Brian Lundstrom, President
760-640-6383
bl@intlstemcell.com

Click here to view the list of recent Press Releases from International Stem Cell Corporation
Promote Your Business